

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Sisram Medical Ltd**  
**復銳醫療科技有限公司\***  
*(Incorporated in Israel with limited liability)*  
**(Stock Code: 1696)**

**MAJOR AND CONNECTED TRANSACTIONS  
AND  
CONTINUING CONNECTED TRANSACTIONS  
AMENDMENT TO SUBLICENSE AGREEMENT**

Reference is made to the announcement (the “**Announcement**”) of Sisram Medical Ltd (the “**Company**”) dated October 26, 2022 in relation to the entering into an amended sublicense agreement (the “**Sublicense Agreement**”) between Sisram Tianjin and Fosun Industrial. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement unless otherwise defined herein.

The Board announces that, as Fosun Industrial already incurred and paid certain cost and expenses in respect of the Licensed Product as explained in the Announcement, the nature of license arrangement under the Sublicense Agreement is to allow the Company to enjoy the benefits from the commercialization of the Licensed Product, the Licensed Product has already obtained the BLA for the aesthetic indications of the Licensed Product from FDA and considerable period of time has passed since the entering into of the original sublicense agreement dated July 14, 2021, on December 15, 2022, Sisram Tianjin entered into an Amendment to Sublicense Agreement (the “**Amendment to Sublicense Agreement**”) with Fosun Industrial to amend the Sublicense Agreement that (i) the Upfront Payment shall be made within 30 Business Days of the date of the Sublicense Agreement; (ii) if Sisram Tianjin fails to receive the approval of its board of directors and/or shareholders that is necessary for the transactions to proceed in compliance with applicable laws (the “**Approval**”) within six (6) months of the date of the Sublicense Agreement, Fosun Industrial should refund all and any of the payment made by Sisram Tianjin under the Sublicense Agreement to Sisram Tianjin promptly without any interest; and (iii) if Sisram Tianjin fails to receive the Approval within six (6) calendar months of the date of the Sublicense Agreement, the Sublicense Agreement shall lapse automatically.

The Circular, which will contain, among other things, (i) details of the Sublicense Agreement (including the Amendment to the Sublicense Agreement), (ii) a letter from the Independent Board Committee containing its recommendation to the Independent Shareholders, (iii) a letter from the Independent Financial Adviser containing its advice to the Independent Board Committee and the Independent Shareholders in connection with the Amended Sublicense Agreement (including the transactions contemplated thereunder) and (iv) notice of the EGM, will be despatched to the Shareholders on or before 23 December 2022.

On behalf of the Board  
**Sisram Medical Ltd**  
復銳醫療科技有限公司\*  
**Yi LIU**  
*Chairman*

Hong Kong, December 16, 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non – executive Directors.*

\* *for identification purpose only*